1 nti-glomerular basement membrane disease, 2;
oxalosis,
2; and miscellaneous, 2.
2 Among the patients with
oxalosis,
56 patients had a liver transplant followed by
3 kidney and many other tissues, with systemic
oxalosis and ESRD being a common outcome.
4 nal failure early in life, advanced systemic
oxalosis,
and a formidable mortality rate.
5 mias, familial hypercholesterolemia, primary
oxalosis,
and factor IX deficiency, among others, might
6 nsplant recipients from 1988 to 1998 who had
oxalosis as their primary diagnosis for their ESRD.
7 Indications for LTx were
oxalosis (
four), congenital hepatic fibrosis (two), cyst
8 Indications for KTx were
oxalosis (
four), drug-induced (four), polycystic kidney
9 although concern exists about recurrence of
oxalosis in the transplanted kidney.
10 survival in renal transplant recipients with
oxalosis is similar to other transplant recipients with
11 Oxalosis,
or calcium oxalate deposition in the tissues,
12 Oxalosis patients receiving a KTA had a significantly wo
13 death-censored graft survival compared with
oxalosis patients who receive a cadaveric or living-dono
14 indicating poor renal allograft survival for
oxalosis patients who receive a renal transplant alone.
15 -censored graft survival (76%) compared with
oxalosis patients who received a KTA (47.9%, P<0.001) an
16 In addition,
oxalosis patients who received a living-donor KTA had si
17 death-censored graft survival compared with
oxalosis patients who received a LKTx (22% vs. 64%, P<0.
18 In contrast,
oxalosis patients who received a LKTx had a significantl
19 Unadjusted death-censored graft survival for
oxalosis patients with a cadaveric or living-donor KTA o
20 For
oxalosis patients with minor enzyme deficiencies, renal
21 In this study, a case of renal
oxalosis probably secondary to excessive parenteral vita
22 Patient survival for
oxalosis recipients with a KTA or a LKTx was not signifi
23 Secondary
oxalosis represents a possible cause of delayed recovery
24 raft survival for transplant recipients with
oxalosis to a reference group with ESRD secondary to glo
25 Patients with
oxalosis who receive a LKTx have superior death-censored
26 th-censored graft survival for patients with
oxalosis who received a LKTx or a KTA.
27 leading to renal failure, followed by tissue
oxalosis with life-threatening complications.